Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo
Open Access
- 14 November 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (22) , 7130-7140
Abstract
Purpose: Choriocarcinoma (CC) is the most malignant gestational trophoblastic disease that often develops from complete hydatidiform moles (CHM). Neither the mechanism of CC development nor its progression is yet characterized. We recently identified endocrine gland–derived vascular endothelial growth factor (EG-VEGF) as a novel key placental growth factor that controls trophoblast proliferation and invasion. EG-VEGF acts via two receptors, PROKR1 and PROKR2. Here, we demonstrate that EG-VEGF receptors can be targeted for CC therapy. Experimental Design: Three approaches were used: (i) a clinical investigation comparing circulating EG-VEGF in control (n = 20) and in distinctive CHM (n = 38) and CC (n = 9) cohorts, (ii) an in vitro study investigating EG-VEGF effects on the CC cell line JEG3, and (iii) an in vivo study including the development of a novel CC mouse model, through a direct injection of JEG3-luciferase into the placenta of gravid SCID-mice. Results: Both placental and circulating EG-VEGF levels were increased in CHM and CC (×5) patients. EG-VEGF increased JEG3 proliferation, migration, and invasion in two-dimensional (2D) and three-dimensional (3D) culture systems. JEG3 injection in the placenta caused CC development with large metastases compared with their injection into the uterine horn. Treatment of the animal model with EG-VEGF receptor's antagonists significantly reduced tumor development and progression and preserved pregnancy. Antibody-array and immunohistological analyses further deciphered the mechanism of the antagonist's actions. Conclusions: Our work describes a novel preclinical animal model of CC and presents evidence that EG-VEGF receptors can be targeted for CC therapy. This may provide safe and less toxic therapeutic options compared with the currently used multi-agent chemotherapies. Clin Cancer Res; 23(22); 7130–40. ©2017 AACR.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- Prokineticin 2 is an endangering mediator of cerebral ischemic injuryProceedings of the National Academy of Sciences, 2012
- Trophoblastic vasculogenic mimicry in gestational choriocarcinomaLaboratory Investigation, 2011
- Prokineticins in angiogenesis and cancerCancer Letters, 2010
- Role of EG‐VEGF in human placentation: Physiological and pathological implicationsJournal of Cellular and Molecular Medicine, 2008
- Antiproliferative activity of CCN3: Involvement of the C‐terminal module and post‐translational regulationJournal of Cellular Biochemistry, 2007
- Implications of Endocrine Gland–Derived Vascular Endothelial Growth Factor/Prokineticin-1 Signaling in Human Neuroblastoma ProgressionClinical Cancer Research, 2007
- Heterophile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay2003
- Identification and Molecular Characterization of Two Closely Related G Protein-coupled Receptors Activated by Prokineticins/Endocrine Gland Vascular Endothelial Growth FactorJournal of Biological Chemistry, 2002
- Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Human Placenta and Fetal Membranes in Relation to Preterm and Term LaborThe Journal of Clinical Endocrinology & Metabolism, 2002
- Falsely elevated human chorionic gonadotropin leading to unnecessary therapy1Obstetrics & Gynecology, 2001